Company
History

Trinity Biotech was founded in 1992 and listed on the NASDAQ market shortly after its formation.

Through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products.

Today Trinity Biotech is listed on the NASDAQ Global Select Market, and has approximately 18 million American Depository Shares.

The Company, which has its headquarters in Bray, Ireland, employs in excess of 700 people worldwide and markets its portfolio of over 500 products to customers in 80 countries around the world.

Trinity Biotech’s growth to date has involved the following:

1994
March
Acquired Disease Detection International, Irvine, California, USA.
1996
July  
Launched Uni-Gold™ HIV and One-step test
1997
February
Acquired Clark Laboratories, Jamestown, New York, USA.
July  
Acquired Centocor, Cambridge, UK
1998
March
Opened 50,000 sq. ft. manufacturing facility in Bray, Ireland
June
Acquired Hormone & Drugs of Abuse from Diatech, Boston, USA
July
Acquired Macra® Lp(a) from Strategic Diagnostics Inc., USA
September
Acquired HIV product line from Cambridge Diagnostics, USA
October
Acquired MicroTrak® product line from Dade Behring, USA
2000
 
March  
Acquired MarDx® Diagnostics, Inc., Carlsbad, California, USA.
December
Acquired assets and goodwill of Bartels Inc., Oregon, USA
2001
 
October
Establishment of Trinity Biotech German sales and marketing subsidiary
December
Acquired Biopool, Ventura, California, USA.
2002
 
August
Acquired coagulation division of Sigma Diagnostics, USA.

October  

Establishment of Trinity Biotech UK sales & marketing subsidiary.
December
Acquired Specialty Clinical Chemistry, Sigma Diagnostics, USA
2003
 
December
FDA clearance for Uni-Gold™ Recombigen® HIV test
2004
April
Acquired Adaltis US, Inc
April
Acquires Fitzgerald Industries International, Mass, USA.
November  
Received US CLIA Waiver for Uni-Gold™ Recombigen® HIV Test
2005
 
March
Acquired Research Diagnostics Inc., Flanders, New Jersey, USA.
July
Acquired Primus Corporation of Kansas City, Missouri, USA
2006
 
June
Acquired coagulation division of bioMerieux, Lyon, France